Mueller-Ladner, Ulf (2004) Cost effectiveness of biologics in the treatment of rheumatoid arthritis. INTERNIST, 45 (12). pp. 1402-1406. ISSN 0020-9554, 1432-1289
Full text not available from this repository. (Request a copy)Abstract
Since the biologics have been introduced in clinical rheumatology, the landscape for medication of rheumatoid arthritis has changed substantially. A completely new family of drugs had to be evaluated for efficacy with regard to its impact on amelioration of disease activity but also with regard to long-term side effects and costs. This evaluation of effectiveness of biologics belongs to the most intensively discussed topics in rheumatology, and at present, only for the clinical side adequate answers can be obtained from the published data. On the other hand, more long-term observation and prospective studies are needed to be able to answer the question of real cost-effectiveness adequately. However, when all current data are summarized, the cost for a TNF-inhibitor in regard of one quality-adjusted life-year ranges below the internationally recommended critical amount of 40.000 E.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ANTITUMOR NECROSIS FACTOR; RECEIVING CONCOMITANT METHOTREXATE; INTERLEUKIN-1 RECEPTOR ANTAGONIST; ALPHA MONOCLONAL-ANTIBODY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; INFLAMMATORY DISEASES; BLOCKING-AGENTS; THERAPY; ETANERCEPT; rheumatoid arthritis; biologics; TNF-inhibitors; effectiveness; quality-adjusted life-year |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 21 Jun 2021 10:01 |
| Last Modified: | 21 Jun 2021 10:01 |
| URI: | https://pred.uni-regensburg.de/id/eprint/36906 |
Actions (login required)
 |
View Item |
